Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,672 INR | -0.43% | +4.49% | +12.16% |
Feb. 02 | Transcript : Poly Medicure Limited, Q3 2024 Earnings Call, Feb 02, 2024 | |
Jan. 31 | Poly Medicure Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 62.86 times its estimated earnings per share for the ongoing year.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+12.16% | 1.93B | C | ||
-5.15% | 181B | C+ | ||
+2.46% | 112B | C | ||
-2.79% | 67.92B | A | ||
+4.39% | 50.1B | B- | ||
+7.94% | 44.27B | B- | ||
+9.39% | 40.41B | B+ | ||
+24.95% | 31.95B | B | ||
-0.19% | 25.82B | A- | ||
+17.27% | 25.29B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- POLYMED Stock
- Ratings Poly Medicure Limited